Zelenev A, et al. - As complementary interventions like opioid agonist therapies (OAT) and syringe services programs (SSP) may improve the prevention impact of HCV treatment as prevention (TasP) strategies, researchers conducted this modeling study to determine the influence of scaling up the combination of OAT and SSP with HCV TasP in a network of people who inject drugs (PWID) in the US. They deployed a stochastic block model using empirical data from Hartford, Connecticut in order to simulate an injection network of 1,574 PWID. A susceptible-infected model was employed for HCV and HIV to appraise the effectiveness of various HCV TasP strategies, including in combination with OAT and SSP scale-up, over 20 years. At the highest HCV prevalence (75%), when OAT coverage is improved from 10% to 40%, combined with HCV therapy of 10 % per year, reduction in the time to obtain micro-elimination occurs from 18.4 to 11.6 years. For micro-elimination of HCV, the most effective strategy was scale up of HCV TasP. However, OAT scale-up may be synergistic toward accomplishing micro-elimination goals when HCV pervasiveness surpasses 60% and when HCV treatment coverage is 10 per 100 PWID per year or lower.